

02/27/02

PTO/SB/05 (03-01)  
Approved for use through 10/31/2002. OMB 0651-0032  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

**UTILITY  
PATENT APPLICATION  
TRANSMITTAL**

U.S. PTD  
10/18/76

ADDRESS TO: Assistant Commissioner for Patents  
Box Patent Application  
Washington, D.C. 20231

1. ☒ **Fee Transmittal Form (e.g., PTO/SB/17)**  
(Submit an original, and a duplicate for fee processing)

2. ☐ **Applicant claims small entity status.**  
See 37 CFR 1.27.

3. ☒ **Specification** [Total Pages ]  
(preferred arrangement set forth below)

  - Descriptive title of the invention
  - Cross Reference to Related Applications
  - Statement Regarding Fed sponsored R & D
  - Reference to sequence listing, a table, or a computer program listing appendix
  - Background of the Invention
  - Brief Summary of the Invention
  - Brief Description of the Drawings (if filed)
  - Detailed Description
  - Claim(s)
  - Abstract of the Disclosure

4. ☒ **Drawing(s) (35 U.S.C. 113)** [Total Sheets ]

5. **Oath or Declaration** [Total Pages ]

  - a. ☐ Newly executed (original or copy)
  - b. ☒ **Copy from a prior application (37 CFR 1.63(d))**  
(for continuation/divisional with Box 18 completed)
    - i. ☐ **DELETION OF INVENTOR(S)**  
Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b).

6. ☐ **Application Data Sheet.** See 37 CFR 1.76

7. ☐ **CD-ROM or CD-R in duplicate, large table or Computer Program (Appendix)**

8. **Nucleotide and/or Amino Acid Sequence Submission**  
(if applicable, all necessary)

  - a. ☒ **Computer Readable Form (CRF)**
  - b. **Specification Sequence Listing on:**
    - i. ☐ CD-ROM or CD-R (2 copies); or
    - ii. ☒ paper
  - c. ☒ **Statements verifying identity of above copies**

9. ☐ Assignment Papers (cover sheet & document(s))

10. ☐ 37 CFR 3.73(b) Statement ☐ Power of Attorney  
(when there is an assignee)

11. ☐ English Translation Document (if applicable)

12. ☒ Information Disclosure ☐ Copies of IDS  
Statement (IDS)/PTO-1449 Citations

13. ☒ Preliminary Amendment

14. ☒ Return Receipt Postcard (MPEP 503)  
(Should be specifically itemized)

15. ☐ Certified Copy of Priority Document(s)  
(if foreign priority is claimed)

16. ☐ Nonpublication Request under 35 U.S.C. 122  
(b)(2)(B)(i). Applicant must attach form PTO/SB/35  
or its equivalent.

17. ☐ Other:

☒ Continuation    ☐ Divisional    ☐ Continuation-in-part (CIP) of prior application No.: 09/549,090Group / Art Unit 1653

For CONTINUATION OR DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.

☒ *Customer Number or Bar Code Label*

or ☐ Correspondence address below

(Insert Customer No. on Airtech barcode label here)

PATENT TRADEMARK OFFICE

Fax

Date	27 Feb. 02
------	------------

Express Mail Label No.  
EV022025865US





PK3065US3

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: DOWER et al.

Application No.: To be assigned

Filing Date: Concurrently herewith

Title: *PEPTIDES AND COMPOUNDS THAT BIND  
TO A THROMBOPOIETIN RECEPTOR*STATEMENT TO SUPPORT FILING AND SUBMISSION IN ACCORDANCE  
WITH 37 C.F.R. § 1.821-1.825

BOX PATENT APPLICATION

Commissioner for Patents

Washington, DC 20231

Sir:

In connection with a Sequence Listing submitted concurrently herewith, the undersigned hereby states that:

1. the submission, filed herewith in accordance with 37 C.F.R. § 1.821 (g), does not include new matter;
2. the content of the attached paper copy and the attached computer readable copy of the Sequence Listing, submitted in accordance with 37 C.F.R. § 1.821 (c) and (e), respectively, are the same; and
3. all statements made herein of their own knowledge are true and that all statements made on information and belief are believed to be true; and further, that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent resulting therefrom.

Respectfully submitted

February 27, 2002

Date



Virginia C. Bennett

Attorney of Record, Reg. No. 37,092

GlaxoSmithKline  
Corporate Intellectual Property Department  
Five Moore Drive, PO Box 13398  
Research Triangle Park, NC 27709-3398  
Phone: 919-483-1012  
Facsimile: 919-483-7988